Pretherapeutic Comparative Dosimetry of ¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT: Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands allow for labeling with ¹⁸F and radiometals for endoradiotherapy. rhPSMA-7.3 has been designated as a lead compound with promising preclinical data for ¹⁷⁷Lu-rhPSMA-7.3, which has shown higher tumor uptake than ¹⁷⁷Lu-PSMA I&T. In this retrospective analysis, we compared pretherapeutic clinical dosimetry data of both PSMA ligands. Methods: Six patients with metastatic castration-resistant prostate cancer underwent both ¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T pretherapeutic dosimetry. Whole-body scintigraphy was performed at 1 h, 4 h, 24 h, 48 h, and 7 d after injection. Regions of interest covering the whole body, organs, bone marrow, and tumor lesions were drawn for eac

SUBMITTER: Feuerecker B 

PROVIDER: S-EPMC9157737 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature